This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second look at the potential use of Nipocalimab currently being evaluated to treat patients at risk for HDFN in the UNITY clinical trial by Janssen Pharmaceuticals
Ticker(s): JNJWho's the expert?
Institution: Wilmington health
- 10 years in private OBGYN practice multi specialty group
- treats 400-450 for candida infections per year- 150 of which are refractory cases
- has prescribed brexafemme and is aware of interim data from ongoing Phase 3 FURI Study of Ibrexafungerp for refractory candida infections showing it is helpful for refractory cases and also systemic cases
Interview GoalA look at the potential use of Nipocalimab currently being evaluated to treat patients at risk for HDFN in the UNITY clinical trial by Janssen Pharmaceuticals.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
